GlassScriptPhysician profile
Noel Munar Chamian
NPI 1376533059
$18,154.97
in general payments reported to CMS, 2019-2025
48 companies · $2,749 in 2025
The $2,749 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,788 · 2020: $1,798 · 2021: $2,705 · 2022: $3,038 · 2023: $3,237 · 2024: $2,840 · 2025: $2,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,769 · Education: $57.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,769.10 |
| Education | $57.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,892.62 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $2,164.61 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $1,171.36 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $1,101.54 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $1,041.35 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $1,032.23 | 2020-2025 | Ubrelvy, Qulipta, Synthroid |
| Esperion Therapeutics, INC. | $860.70 | 2020-2025 | Nexletol |
| Pfizer INC. | $823.46 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $804.25 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $666.93 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $612.04 | 2019-2025 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $431.57 | 2019-2025 | Zoryve |
| Amarin Pharma, INC. | $319.40 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $306.91 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $233.51 | 2019-2025 | Jynarque |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $209.52 | 2019-2025 | |
| Abbott Laboratories | $194.24 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Allergan, INC. | $178.12 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $172.59 | 2021-2025 | Xifaxan, Trulance |
| Lucid Diagnostics INC. | $156.72 | 2022 | |
| Astellas Pharma US INC | $151.97 | 2019-2024 | Veozah |
| Dexcom, INC. | $145.37 | 2022-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $122.02 | 2021 | |
| Idorsia Pharmaceuticals US INC | $119.07 | 2022-2024 | Quviviq |
| Exact Sciences Corporation | $116.80 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Medicure Pharma INC. | $109.99 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $106.95 | 2022 | |
| Intra-Sana Laboratories | $104.51 | 2023-2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Ibsa Pharma INC. | $96.00 | 2019-2022 | |
| Corcept Therapeutics | $88.42 | 2024 | Korlym |
| Horizon Therapeutics Plc | $82.80 | 2019-2023 | Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $72.87 | 2019-2024 | Cuvitru |
| Alexion Pharmaceuticals, INC. | $62.68 | 2020-2025 | Ultomiris |
| Halozyme INC | $56.71 | 2023 | |
| Merck Sharp & Dohme LLC | $55.93 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $54.45 | 2019-2020 | |
| Daiichi Sankyo INC. | $33.67 | 2019-2024 | Injectafer |
| Nevro Corp. | $32.39 | 2023 | Senza |
| Shield Therapeutics INC | $23.58 | 2025 | |
| Boston Scientific Corporation | $20.58 | 2020 | |
| Avion Pharmaceuticals | $19.54 | 2020 | |
| Eisai INC. | $18.79 | 2021 | |
| Currax Pharmaceuticals LLC | $17.01 | 2021 | |
| Bioventus LLC | $15.53 | 2020 | |
| Bardy Diagnostics, INC. | $14.50 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $13.92 | 2019 | |
| Antares Pharma, INC. | $13.66 | 2025 | Xyosted |
| E.R. Squibb & Sons, L.L.C. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noel Chamian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.